Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569985 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00569985 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT00569985, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This pilot clinical trial studies biological therapy in treating patients with acquired immune deficiency syndrome (AIDS)-related lymphoma undergoing stem cell transplant. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving biological therapy as part of the stem cell transplant may be more effective in treating patients with AIDS-related lymphoma
Interventions
- DRUG cyclophosphamide
- DRUG etoposide
- PROCEDURE autologous hematopoietic stem cell transplantation
- DRUG carmustine
- BIOLOGICAL lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-06 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569985
The ClinicalTrials.gov registry entry for NCT00569985 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00569985 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569985 about?
NCT00569985 is a clinical study titled "Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma". This pilot clinical trial studies biological therapy in treating patients with acquired immune deficiency syndrome (AIDS)-related lymphoma undergoing stem cell transplant. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing the...
What is the current status of trial NCT00569985?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-06. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT00569985?
The interventions under investigation include: cyclophosphamide (DRUG), etoposide (DRUG), autologous hematopoietic stem cell transplantation (PROCEDURE), carmustine (DRUG), lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00569985?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.